Search Results - "Johnson, DH"

How Does Nonpenetrating Glaucoma Surgery Work? Aqueous Outflow Resistance and Glaucoma Surgery by Johnson, Douglas H, Johnson, Mark

“…Histologic, experimental, and theoretical studies of the aqueous outflow pathways point toward the juxtacanalicular region and inner wall of Schlemm's canal as…”
Get full text

Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents by Menzies, Dhananjai J, Dorsainvil, Pierre A, Cunha, Burke A, Johnson, Diane H

Get more information

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer by Burdett, Sarah, Pignon, Jean Pierre, Tierney, Jayne, Tribodet, Helene, Stewart, Lesley, Le Pechoux, Cecile, Aupérin, Anne, Le Chevalier, Thierry, Stephens, Richard J, Arriagada, Rodrigo, Higgins, Julian P T, Johnson, David H, Van Meerbeeck, Jan, Parmar, Mahesh K B, Souhami, Robert L, Bergman, Bengt, Douillard, Jean-Yves, Dunant, Ariane, Endo, Chiaki, Girling, David, Kato, Harubumi, Keller, Steven M, Kimura, Hideki, Knuuttila, Aija, Kodama, Ken, Komaki, Ritsuko, Kris, Mark G, Lad, Thomas, Mineo, Tommaso, Piantadosi, Steven, Rosell, Rafael, Scagliotti, Giorgio, Seymour, Lesley K, Shepherd, Frances A, Sylvester, Richard, Tada, Hirohito, Tanaka, Fumihiro, Torri, Valter, Waller, David, Liang, Ying

“…To evaluate the effects of administering chemotherapy following surgery, or following surgery plus radiotherapy (known as adjuvant chemotherapy) in patients…”
Get more information

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data by Arriagada, R, Auperin, A, Burdett, S, Higgins, J P, Johnson, D H, Le Chevalier, T, Le Pechoux, C, Parmar, M K B, Pignon, J P, Souhami, R L, Stephens, R J, Stewart, L A, Tierney, J F, Tribodet, H, van Meerbeeck, J

“…Summary Background Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable non-small-cell lung cancer. We undertook…”
Get full text

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer by Herbst, Roy S, Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E, Sandler, Alan, Kris, Mark G, Tran, Hai T, Klein, Pam, Li, Xin, Ramies, David, Johnson, David H, Miller, Vincent A

“…Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with…”
Get full text

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis by De Ruysscher, D., Lueza, B., Le Péchoux, C., Johnson, D.H., O'Brien, M., Murray, N., Spiro, S., Wang, X., Takada, M., Lebeau, B., Blackstock, W., Skarlos, D., Baas, P., Choy, H., Price, A., Seymour, L., Arriagada, R., Pignon, J.-P., De Ruysscher, D., Le Pechoux, C., Lueza, B., Paris, E., Pignon, J.P., Pijls-Johannesma, M., Veillard, A.S., Arriagada, Rodrigo, Baas, Paul, Blackstock, William, Chevret, Sylvie, Choy, Hak, Crawford, Jeffrey, Dafni, Urania, Dahlberg, Suzanne, De Ruysscher, Dirk, Hackshaw, Allan, Hasan, Baktiar, Johnson, David H., Le Pechoux, Cécile, Lebeau, Bernard, Lovato, James, Lueza, Béranger, Murray, Nevin, O’Brien, Mary, Paris, Emmanuelle, Pignon, Jean-Pierre, Pijls-Johannesma, Madelon, Price, Allan, Spiro, Stephen, Seymour, Lesley, Shibata, Taro, Skarlos, Dimosthenis, Takada, Minoru, Veillard, Anne-Sophie, Wang, Xiaofei

“…Chemotherapy (CT) combined with radiotherapy is the standard treatment of ‘limited-stage’ small-cell lung cancer. However, controversy persists over the…”
Get full text

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data by Navani, Neal, Fisher, David J, Tierney, Jayne F, Stephens, Richard J, Burdett, Sarah

“…Clinical staging of non-small cell lung cancer (NSCLC) helps determine the prognosis and treatment of patients; few data exist on the accuracy of clinical…”
Get full text

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer by JOHNSON, David H, FEHRENBACHER, Louis, HOLMGREN, Eric, KABBINAVAR, Fairooz, NOVOTNY, William F, HERBST, Roy S, NEMUNAITIS, John J, JABLON, David M, LANGER, Corey J, DEVORE, Russell F, GAUDREAULT, Jacques, DAMICO, Lisa A

“…To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. In a…”
Get full text

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer by Schiller, Joan H, Harrington, David, Belani, Chandra P, Langer, Corey, Sandler, Alan, Krook, James, Zhu, Junming, Johnson, David H

“…Four combinations of chemotherapy were compared in patients with advanced non–small-cell lung cancer. No one regimen appeared to be superior to the others. The…”
Get full text

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib by EBERHARD, David A, JOHNSON, Bruce E, KLEIN, Pam, MILLER, Vincent A, OSTLAND, Michael A, RAMIES, David A, SEBISANOVIC, Dragan, STINSON, Jeremy A, ZHANG, Yu R, SESHAGIRI, Somasekar, HILLAN, Kenneth J, AMLER, Lukas C, GODDARD, Audrey D, HELDENS, Sherry L, HERBST, Roy S, INCE, William L, JÄNNE, Pasi A, JANUARIO, Thomas, JOHNSON, David H

“…Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with…”
Get full text

American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003 by PFISTER, David G, JOHNSON, David H, SOMERFIELD, Mark R, AZZOLI, Christopher G, SOUSE, William, SMITH, Thomas J, BAKER, Sherpas JR, OLAK, Jemi, STOVER, Diane, STRAWN, John R, TURRISI, Andrew T

Get full text

The Insignificance of Statistical Significance Testing by Johnson, Douglas H.

“…Despite their wide use in scientific journals such as The Journal of Wildlife Management, statistical hypothesis tests add very little value to the products of…”
Get full text

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials by BELL, Daphne W, LYNCH, Thomas J, KREBS, Annetta D, JOHNSON, David H, GIACCONE, Gmseppe, HERBST, Roy S, MANEGOLD, Christian, FUKUOKA, Masahiro, KRIS, Mark G, BASELGA, José, OCHS, Judith S, HABER, Daniel A, HASERLAT, Sara M, HARRIS, Patricia L, OKIMOTO, Ross A, BRANNIGAN, Brian W, SGROI, Dennis C, MUIR, Beth, RIEMENSCHNEIDER, Markus J, IACONA, Renee Bailey

“…Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor…”
Get full text

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer by HERBST, Roy S, JOHNSON, David H, HONG, Waun K, TRAN, Hai, TSAO, Anne, DONG XIE, RAMIES, David A, MASS, Robert, SESHAGIRI, Somasekar, EBERHARD, David A, KELLEY, Sean K, SANDLER, Alan, MININBERG, Eric, CARBONE, David P, HENDERSON, Ted, KIM, Edward S, BLUMENSCHEIN, George JR, LEE, Jack J, LIU, Diane D, TRUONG, Mylene T

“…Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib…”
Get full text

Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial by Langer, Corey J., Manola, Judith, Bernardo, Patricia, Kugler, John W., Bonomi, Philip, Cella, David, Johnson, David H.

“…Background: Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy. We performed a retrospective analysis of…”
Get full text

Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data by Hoang, Tien, Xu, Ronghui, Schiller, Joan H, Bonomi, Philip, Johnson, David H

“…(1) Identify clinical factors that can be used to predict survival in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) treated with…”
Get full text

The Importance of Replication in Wildlife Research by Johnson, Douglas H.

“…Wildlife ecology and management studies have been widely criticized for deficiencies in design or analysis. Manipulative experiments-with controls,…”
Get full text

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis aEuro by De, Ruysscher D, Lueza, B, Le, Pechoux C, Johnson, DH, O'Brien, M, Murray, N, Spiro, S, Wang, X, Takada, M, Lebeau, B

Get full text

Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non–Small-Cell Lung Cancer by BELANI, Chandra P, WEI WANG, JOHNSON, David H, WAGNER, Henry, SCHILLER, Joan, VEEDER, Michael, MEHTA, Minesh

“…To compare once-daily radiation therapy (qdRT) with hyperfractionated accelerated radiation therapy (HART) after two cycles of induction chemotherapy. Eligible…”
Get full text

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer by Keller, Steven M, Adak, Sudeshna, Wagner, Henry, Johnson, David H

“…Background. Mediastinal lymph node dissection (MLND) is an integral part of surgery for non-small cell lung cancer (NSCLC). To compare the impact of systematic…”
Get full text